Using Tau PET/CT Imaging to Understand Alzheimer's Disease
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)
This study is testing how Tau PET/CT scans can help us understand the differences in symptoms and brain changes in older adults with Mild Cognitive Impairment or Alzheimer's Disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 120 Years |
| Sex | All |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 2 sites (Boston, Massachusetts and 1 other locations) |
| Trial ID | NCT05658913 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect Tau PET/CT imaging data from older adults diagnosed with Mild Cognitive Impairment or Alzheimer's Disease. Participants, who are already enrolled in the Mismatch Prospective Cohort Study, will undergo PET/CT scans using the radiotracer AV-1451 to explore the relationship between tau pathology and various clinical and cognitive biomarkers. The findings are expected to shed light on the phenotypic variability of Alzheimer's Disease and related conditions.
Who should consider this trial
Good fit: Ideal candidates include older adults diagnosed with Mild Cognitive Impairment or Alzheimer's Disease who are enrolled in the Mismatch Prospective Cohort Study.
Not a fit: Patients with significant medical or psychiatric conditions that could compromise their safety or participation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of Alzheimer's Disease, potentially leading to improved diagnostic and therapeutic strategies.
How similar studies have performed: Previous studies utilizing tau imaging have shown promise in understanding Alzheimer's pathology, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Enrolled in MPC study (Protocol 850160 at UPenn; Protocol 2022P002447 at MGH). 2. Reliable study partner to accompany participant to the PET/CT scan 3. A brain MRI must be performed within 6 months prior to their study AV-1451 TAU PET/CT scan date and be deemed of adequate quality that the scan may be used for study analysis, including 3T high-resolution imaging of medial temporal lobe structures. Exclusion Criteria: 1. Have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study. 2. Have evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET/CT scan. 3. Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician. 4. Have a history of significant ongoing alcohol or substance abuse based on self- report. 5. Female participants of child-bearing age will not be able to participate in this study, determined by self-report.
Where this trial is running
Boston, Massachusetts and 1 other locations
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: David A. Wolk — University of Pennsylvania Department of Neurology at the Perelman School of Medicine
- Study coordinator: Jacqueline Lane
- Email: Jacqueline.Lane@pennmedicine.upenn.edu
- Phone: 610-299-1243
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.